Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIONEER: Narlaprevir with Ritonavir and PEG-INF/RBV in Chronic Hepatitis C
NCT03833362Phase 3Completed
- Sponsor
- R-Pharm
- Start
- May 2014
- Primary completion
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of narlaprevir in hepatitis C (HCV) (4 arms), sponsored by R-Pharm. Primary endpoint: Sustained Virologic Response. Started May 2014; status: completed.
02
Drugs
narlaprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT03833362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03833362.